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Background. Nonadherence to medication is a common problem after kidney transplantation. The aim of this study was to explore
attitudes towards medication, adherence, and the relationship with clinical outcomes.Method. Kidney recipients participated in a
Q-methodological study 6 weeks after transplantation. As a measure of medication adherence, respondents completed the Basel
Assessment of Adherence to ImmunosuppressiveMedications Scale (BAASIS©-interview). Moreover, the intrapatient variability in
the pharmacokinetics of tacrolimus was calculated, which measures stability of drug intake. Data on graft survival was retrieved
from patient records up to 2 years after transplantation. Results. 113 renal transplant recipients (19–75 years old) participated in the
study. Results revealed three attitudes towards medication adherence—attitude 1: “confident and accurate,” attitude 2: “concerned
and vigilant,” and attitude 3: “appearance oriented and assertive.” We found association of attitudes with intrapatient variability in
pharmacokinetics of tacrolimus, but not with self-reported nonadherence or graft survival. However, self-reported nonadherence
immediately after transplantation was associated with lower two-year graft survival.Conclusion.These preliminary findings suggest
that nonadherence shortly after kidney transplantation may be a risk factor for lower graft survival in the years to follow. The
attitudes to medication were not a risk factor.
1. Introduction
Kidney transplant patients are required to take lifelong
immunosuppressive medication to prevent graft rejection.
Nonadherence to immunosuppressive medication is a com-
mon issue and increases over time. Both dosage and timing
of medication are crucial. Failure to take the medication as
prescribed is a risk factor for (late) acute rejection, (late) graft
failure/loss, and patient mortality [1–4].
Among renal transplant patients, on average 36% of
patients per year are reported to be nonadherent to immuno-
suppressive medication with estimates ranging from 2 to
67% [2, 5–7]. A number of patient, practitioner, and regime
related factors have been shown to be related to adherence
after renal transplantation. The number and frequency of
medication, as well as the relationship, communication, and
trust between the patient and health care provider, are likely
to influence adherence [3]. Nonadherence is particularly a
problem among adolescent transplant recipients. Rates of
nonadherence have also been found to be related to factors
such as level of social support, education, and socioeconomic
status [3, 8].There is also evidence that nonadherence prior to
transplantation is an independent predictor of nonadherence
after transplantation [5, 9].
As nonadherence is a behavioural rather than a medical
issue, many studies have focused on exploring possible
psychological and other modifiable predictors [2, 3, 10].
Psychological well-being, such as depression, can affect the
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extent to which an individual is adherent to the medication
regime [11]. In a previous study we reported clusters of
attitudes which may indicate risk of poorer adherence to
medication among young adult renal transplant patients [12].
This was a population of young adults who had varying
time since transplantation. Evidence suggests that adherence
immediately after transplantation is often high but gradu-
ally declines over time [2], although some authors suggest
that nonadherence might be “early and pervasive” among
renal transplant patients [4]. Schmid-Mohler et al. [10] used
the integrative model of behavioural prediction and found
that forgetfulness/interruption of daily routine was the only
significant predictor for nonadherence. In their later work
[13] they found that nonadherence was significantly asso-
ciated with patients’ beliefs about their immunosuppressive
medicines. The aim of this study was to gain greater insight
into attitudes towards the immunosuppressive medication
regime shortly after kidney transplantation. Furthermore, to
explore the relationship between adherence to medication
and clinical outcomes in the years following transplantation.
2. Methods
2.1. Participants. All consecutive patients who received either
a living or deceased donor kidney transplant in the Erasmus
Medical Centre, Rotterdam, betweenAugust, 2010, andOcto-
ber, 2011, were invited to participate in the study. The inclu-
sion criteria required that kidney transplant patients were
older than 18 years, had a functioning graft six weeks after
transplantion, and had a sufficient level of understanding and
speaking of the Dutch language. For clinical endpoints we
had a follow-up time of at least two years after transplantation
(until October 31, 2013).
All participants provided written consent for partici-
pation and the study was approved by the Medical Ethics
Committee of the Erasmus Medical Centre.
2.2. Measures and Procedure. To explore attitudes towards
medication after kidney transplantation we used Q-
methodology. This is a method that combines aspects
of qualitative and quantitative methods and provides a
foundation for the systematic study of subjectivity (e.g.,
peoples’ viewpoints or beliefs and in this case attitudes to
the immunosuppressive medication regime after kidney
transplantation) [14, 15]. The results of a Q-methodological
study can be used to describe a population of viewpoints,
not a population of people [16, 17]. In previous studies we
generated statements for young adults and the elderly using
the WHO dimensions of adherence [8, 18]: socioeconomic
related factors, health care team or health system related
factors, condition related factors, treatment related factors,
and patient related factors. This was done based on an
iterative procedure and consensus [12]. For the current study
the statements were tailored for a more general use with
patients of all ages. The final Q-set consisted of 37 statements








Figure 1:Thegrid that patients used to rank-order the 37 statements.
Respondents were invited to participate in face-to-face
interviews. Patients were interviewed 6 weeks after trans-
plantation during which they were asked to rank-order the
37 statements, using a quasinormal grid ranging from −3
to +3 (Figure 1) [12]. In addition, participants were asked to
explain the ranking of the 2 statements that they agreed with
(+3) and disagreed (−3) the most. The individual rankings of
statements were analysed using by person factor analysis so as
to reveal a limited number of corresponding patterns in the
way the statements were sorted by respondents. Correlation
between individual rankings of statements is viewed as an
indication of similarity in attitude.
The outcome variable was nonadherence. To study non-
adherence effectively we used a combination of measurement
methods, as proposed by Farmer [19]. Firstly, we used
the Basel Assessment of Adherence to Immunosuppressive
Medications Scale (BAASIS©-interview) [20, 21]. This scale
is a self-report instrument that consists of 4 questions on the
taking and timing of medication, drug holidays, reduction of
the dose, and persistence over the past month (Table 2). An
affirmative answer to any of the first 4 questions results in
assignment to the nonadherent group. This scoring is inten-
tionally strict due to an assumption of the underreporting of
nonadherence. Patients also rated their own adherence using
a visual analogue scale from 0% (medication never taken as
prescribed) to 100% (medication always taken as prescribed).
The BAASISmeasure was selected as it is short, reliable, valid,
and sensitive to both timing and taking which is of particular
importance for the immunosuppressive regime after kidney
transplantation [20]. A number of studies have demonstrated
support for the validity of both parts of the instrument [22,
23]. Specificity and sensitivity of the visual analogue scale
have been shown to be high [22].
Secondly, we calculated patient intraindividual variability
in the pharmacokinetics of immunosuppressive medica-
tion, in this case tacrolimus (Prograft) [24]. Whole blood
tacrolimus concentrations in different measurements over
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Table 1: Statements and factor scores.
Statements Posttransplant attitudes
Factor 1 Factor 2 Factor 3
(1) I would rather not tell others that I have a transplant −2 −2 −3
(2) If you forget your medication now and then, it is not a problem −1 −3∗∗ −1
(3) It is more important to enjoy life than to be compliant 0∗∗ −2∗ −1∗
(4) If I do something that is not so healthy, I tend to feel guilty −1∗∗ 0 0
(5) I do not want my life to revolve around my disease +1∗ +2∗ +3∗∗
(6) I do not like to take medication when others are around −1∗∗ −2∗∗ 0∗∗
(7) I have a healthy lifestyle 0 0 0
(8) I am worried that my kidney will be rejected 0∗ +3∗∗ 0∗
(9) I am concerned about my future −3∗∗ 0∗∗ −1∗∗
(10) I am scared I will have to go on dialysis (again) −1∗∗ +2∗∗ −3∗∗
(11) My appearance is not very important to me 0∗∗ −1∗∗ −2∗∗
(12) I struggle with the fact that my medication makes me fatter −1∗∗ 0∗∗ +1∗∗
(13) I often feel gloomy and depressed −3∗∗ −1∗∗ −1∗∗
(14) I have side effects from my medication −1∗∗ 0∗∗ +2∗∗
(15) I can manage my own medication and appointments +1∗∗ +1∗∗ +3∗∗
(16) My loved ones interfere too much with my health −1 −1 −1∗
(17) I receive enough support from friends and/or family +2 +1∗∗ +2
(18) I would like to meet other kidney transplant patients 0 −1 0∗∗
(19) I appreciate it when others remind me to take my medication 0 0∗∗ 0
(20) I am extra careful with this kidney because it is from a loved one +2∗∗ +2∗∗ −1∗∗
(21) I do not mind taking multiple medications a day +1∗∗ 0 0
(22) When I sleep in, I just take my medication later 0∗∗ −1∗∗ −2∗∗
(23) I have problems swallowing larger pills −2 −1 −1
(24) I sometimes forget my medication −2 −3∗ −2
(25) I know what my medications do +1 0 +1
(26) I have a regular daily routine 0 0 0∗
(27) A pillbox is a handy aid +2 0∗∗ +1
(28) I want the medication to stay the same if I feel good 0 −1∗∗ 0
(29) I take my immunosuppressive drugs exactly every twelve hours +3∗∗ +1 +1
(30) I find it reassuring to have my medication with me when I am away from home 0 +1 +1
(31) If I am not sure whether I have already taken my pill, I just take it again −2 −2 −2
(32) The doctors know what is best for me +1∗∗ +1 0
(33) If I do not comply with the regime; it is ok for healthcare professionals to confront me with the consequences +2 +2 +1∗
(34) I find it reassuring that they check my kidney functioning regularly at the outpatient clinic +3∗ +3 +2
(35) I like it when the doctor gives me a say in the treatment +1∗ +1∗ +2∗
(36) I am honest with the doctor about my medication intake +1 +1∗∗ +1
(37) If I take a wrong dose of medication, I let my doctor know 0 0 0
Note: ∗P < 0.05; ∗∗P < 0.01. A “−3” score indicates that a typical kidney transplant patient with that posttransplant attitude would disagree most with that
statement and a “+3” score that (s)he would agree most.
time within patients were used to calculate intraindivid-
ual variability. Patients with a high intrapatient variability
have tacrolimus concentrations that are often outside the
therapeutic window. Underexposure may lead to immune
activation, and overexposure can result in CNI-induced
nephrotoxicity. Both could affect long-term outcome. Borra
et al. [24] showed that high intraindividual variability in the
pharmacokinetics of tacrolimus leads to reduced graft sur-
vival. One of themost likely causes for intrapatient variability
is medication nonadherence. To calculate the intrapatient
variability in tacrolimus concentrations we used the method
previously described by Borra et al. [24].
For the clinical endpoints, we collected information about
rejection (yes/no) and graft failure (yes/no) two years after
transplantation.
2.3. Statistical Analysis. Independent 𝑡-tests and chi-squared
analyses were conducted to test differences between respon-
ders and nonresponders. As the BAASIS overall rating scale
4 Journal of Transplantation
Table 2: Adherence 6 weeks after transplantation as measured with the BAASIS©-interviewa (n = 113).




1a Taking dimension: Do you remember missing a dose of your immunosuppressivemedication (IM) in the past 4 weeks? 9 (8.0)
(i) Once 8 (7.1)
(ii) 2-3 times 1 (0.9)
1b Drug holidays: Do you remember having skipped two or more doses of your IM ina row in the past 4 weeks? 0
2 Timing dimension: Do you remember having taken your IM more than 2 h beforeor after the prescribed dosing time in the past 4 weeks? 12 (10.6)
(i) Once 10 (8.8)
(ii) 2-3 times 1 (0.9)
(ii) 4-5 times 1 (0.9)
3 Reduction of dose: Have you altered the prescribed amount of your IM during thepast 4 weeks without your doctor telling you to do so? 0
4 Persistence: Have you stopped taking your IM completely in the past 4 weekswithout your doctor telling you to do so? 0
Total 19 (16.8)
Part 2c Median(range)
5 Overall adherence rating 100 (77–100)
Note: a©University of Basel, Leuven-Basel Adherence Research Group, Institute of Nursing Science, University of Basel, Belgium, 2005. Permission and
conditions to use the BAASIS can be obtained from sabina.degeest@unibas.ch. bResponse categories for questions 1 to 4 are given on a 6-point scale: (0) no,
(1) once, (2) 2-3 times, (3) 4-5 times, (4) every 2-3 days, and (5) almost daily. cvisual analogue scale ranging from 0% (medication never taken as prescribed)
to 100% (medication always taken as prescribed).
was negatively skewed, a Mann-Whitney test was used to test
the difference on this scale between adherent and nonadher-
ent patients. One-way ANOVA and chi-squared tests were
used to test the association between attitudes and adherence.
When cell values were small, Fisher’s exact tests were used
to test 2 × 2 associations. Survival analyses were calculated
with Kaplan-Meier and life table. Analyses were carried out
using the Statistical Package for Social Sciences, version 20.0.
Q-methodological data were analysed using PQMethod 2.11
developed by Schmolck and Atkinson 2002.
3. Results
3.1. Demographic Characteristics. Between August, 2010, and
October, 2011, 212 kidney transplantations were carried out
in our centre. Of these 212 patients 44 were excluded for
the following reasons: inability to speak the Dutch language
sufficiently (𝑛 = 23), a mental or physical disability (𝑛 = 9),
death prior to inclusion (𝑛 = 4), graft loss (𝑛 = 4), primary
nonfunction (𝑛 = 3), and follow-up at another centre (𝑛 = 1).
Of the 168 kidney patients whowere eligible to participate, 113
patients were included (67.3%). Fifty-five kidney transplant
patients (32.7%) did not want to participate because theywere
not interested (𝑛 = 20) or did not want to stay longer at the
outpatient clinic for the study (𝑛 = 26). Seven did not want to
participate for logistical reasons and 2 were discontent with
their treatment and decided not to participate. Demographic
characteristics of respondents andnonrespondents are shown
in Table 3. Of the 113 participants we had a minimum follow-
up of two years; 35 experienced graft rejection and 5 graft
failures (1 unknown and 4 due to rejection) and 6 patients
died with a functioning graft.
3.2. Attitudes. The analysis of the Q-methodological study
revealed three distinct attitudes towards medication adher-
ence (Table 1). Of the 113 participants 23 did not load
significantly on any of these attitudes or on more than one.
Of the remaining 90 participants, 40 patients defined factor
1, 38 factor 2, and 12 factor 3.
Patients defining the first factor find it important to
take their medication exactly every twelve hours (statement
29). They take good care of their kidney (statement 20)
and have no worries about the future (statement 9) and
are not afraid they have to go on dialysis again (statement
10). They find it reassuring that their kidney function is
checked regularly (statement 34); these patients feel the least
gloomy or depressed (statement 13).They do notmind taking
multiple medicines every day (statement 21) and also indicate
not experiencing many side effects (statement 14).This factor
was labeled “confident and accurate.” These quotes from
participants defining this factor illustrate this attitude profile:
“this kidney was given to me by my wife; I have an obligation to
take good care of this kidney”; “You do not have any influence
on things going wrong; I will do the best I can”.
Patients defining the second factor also found it reassur-
ing that their kidney function is checked regularly (statement
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(n = 55) P value
n (%) n (%)
Age (years)
18–29 9 (8%) 5 (9.1%) 0.804
30–45 27 (23.9%) 8 (14.5%) 0.161
46–64 59 (52.2%) 34 (61.8%) 0.240
65+ 18 (15.9%) 8 (14.5%) 0.816
Gender
Male 73 (64.6%) 37 (67.3%) 0.733
Female 40 (35.4%) 18 (32.7%)
Education level
High 22 (19.5%) 5 (10%) 0.134
Middle 64 (56.6%) 28 (56%) 0.940
Low 27 (23.9%) 17 (34%) 0.180
Unknown 5
Ethnicity
Caucasian 86 (78.9%) 40 (74.1%) 0.489
Asian 9 (8.3%) 4 (7.4%) 0.851
African 10 (9.2%) 4 (7.4%) 0.705
Turkish 2 (1.8%) 3 (5.6%) 0.195
Other 2 (1.8%) 3 (5.6%) 0.195
Unknown 4 1
Kidney transplant
Living donor 89 (78.8%) 42 (76.4%) 0.725
Deceased donor 24 (21.2%) 13 (23.6%)
Number of transplants (median, range) 1 (1–5) 1 (1–3) 0.690
Marital status
Married 69 (63.3%) 28 (51.9%) 0.161
Living together 14 (12.8%) 5 (9.3%) 0.502
Single 16 (14.7%) 19 (35.2%) 0.003
Divorced 8 (7.3%) 1 (1.9%) 0.149
Widow/widower 2 (1.8%) 1 (1.9%) 0.994
Other 4 1
34), but this is more out of fear of graft loss. They are
concerned that their kidney will be rejected (statement 8) and
are afraid to go (back) on dialysis (statement 10). Therefore
they are careful and they do not think it is wise to forget
medication, even if it is only now and then (statement 2).
They would rather be adherent than to enjoy their life to the
fullest (statement 3). This factor was labeled “concerned and
vigilant.” These quotes illustrate this attitude: “I’m always so
worried; after my check-up I always call my doctor for the test
results”; “Rejection is always on my mind; this has an impact
on my life”; “It is so important to stay focused on the regime; I
do not want to blame myself for ruining this kidney; you have
to follow the rules”.
Patients defining the third factor find their appearance
important (statement 11) and are afraid that the medication
will influence their appearance negatively (statement 12).
They do not want their lives to revolve around their disease
(statement 5), although they indicate experiencing side effects
(statement 14). Nevertheless they do not feel the need to be
extra careful with their kidney from a loved one (statement
20), and they are not really concerned that they will have
to go (back) on dialysis (statement 10). They want their own
say in their treatment (statement 35) and feel they are able
to manage their medication and appointments themselves
(statement 15). Therefore this factor was labeled “appearance
oriented and assertive.” These quotes illustrate this attitude:
“I do not feel sick; not everybody knows I have a kidney
transplant”; “I have been a kidney patient for 40 years now, and
I want to be involved”; “In the future I want to do things without
thinking about my disease”; “This kidney is from my mum and
that is special to me, but I am not extra careful with my kidney
because it is from my mum”.
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(n = 94) P value
n (%) n (%)
Age (years)
18–29 2 (10.5%) 7 (7.4%) 0.651
30–45 3 (15.8%) 24 (25.5%) 0.364
46–64 11 (57.9%) 48 (51.1%) 0.587
65+ 3 (15.8%) 15 (16%) 0.985
Gender
Male 11(57.9%) 62 (66%) 0.503
Female 8 (42.1%) 32 (34%)
Education level
High 2 (10.5%) 20 (21.3%) 0.280
Middle 12 (63.2%) 52 (55.3%) 0.529
Low 5 (26.3%) 22 (23.4%) 0.786
Ethnicity
Caucasian 15 (78.9%) 71 (78.9%) 0.995
Asian 0 (0%) 9 (10%) 0.150
African 3 (15.8%) 7 (7.8%) 0.272
Turkish 0 (0%) 2 (2.2%) 0.512
Other 1 (5.3%) 1 (1.1%) 0.220
Unknown 0 4
Kidney transplant
Living donor 16 (84.2%) 73 (77.7%) 0.524
Deceased donor 3 (15.8%) 21 (22.3%)
Number of transplant (median, range) 1 (1-2) 1 (1–5) 1.000
Marital status
Married 12 (63.2%) 57 (60.6%) 0.837
Living together 0 (0%) 14 (14.9%) 0.072
Single 4 (21.1%) 12 (12.8%) 0.345
Divorced 1 (5.3%) 7 (7.4%) 0.735
Widow/widower 1 (5.3%) 1 (1.1%) 0.205
Other 1 (5.3%) 3 (3.2%) 0.656
There was general consensus between participants
regarding a number of statements. In none of the attitudes
patients were ashamed of their transplantation, minded
others knowing about their kidney transplant (statement
1), or experienced problems with swallowing larger pills
(statement 23). All attitudes were neutral about having a
healthy lifestyle (statement 7), taking their medication with
them when they go out of the house (statement 30) and
letting the doctor know if they took a wrong dose of the
medication (statement 37).
3.3. Adherence. The BAASIS-interview revealed that six
weeks after transplantation, 17% (𝑛 = 19) were classified
as nonadherent (missed a dose or >2 hours earlier or later
than prescribed in the past 4 weeks). Nine patients (8%)
had missed a dose in the last month. Twelve patients (11%)
had taken their dose 2 hours before or after the prescribed
time; and two patients had either missed a dose or taken
their dose 2 hours before or after the prescribed time. None
of the patients had altered their dose or completely stopped
taking their medication in the past four weeks (Table 2).
Demographic characteristics of the self-reported nonadher-
ent patients versus the self-reported adherent patients are
shown in Table 4. There were no significant differences in
age, gender, education level, donor kidney, ethnicity, or social
status between these groups.
Patients also rated their own overall adherence from 0 to
100%. A Mann-Whitney test revealed a significant difference
between groups: the adherent group had a median of 100%
and the nonadherent group had a significantly lower median
of 95% (𝑃 < 0.01).
Of the 19 patients who were classified as nonadherent,
8 patients loaded on attitude 1, 4 patients on attitude 2,
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2 patients on attitude 3, and 5 patients did not load on
any specific attitude. There was no significant association
between attitudes and self-reported nonadherence classifica-
tion (𝜒2(2) = 1.344, 𝑃 = 0.476).
In order to calculate the intrapatient variability in
tacrolimus we used a minimum of 3 tacrolimus measure-
ments per patient (𝑛 = 4) and amaximumof 5measurements
per patient (𝑛 = 87). For 7 patients we were not able to
calculate the intrapatient variability because of missing data.
The median intrapatient variability was 14.5% (range of 1.12–
86.3%). As a cut-off we divided the group in tertiles and split
the patients into a group with low intrapatient variability (the
patients in the lowest tertile, 0–11.7%) and a group with high
variability (the patients in the highest tertile, 18.02–100%).
This resulted in 34 patients in the low-variability group,
with a mean variability of 8.9%, and 35 patients with high
variability, with a mean variability of 27.0%. The intrapatient
variability was significantly correlated with attitude profile
(𝜒2(2) = 6.799; 𝑃 = 0.036). Patients with a high variability
loaded more often on the attitude “concerned and vigilant,”
while those with a low variability loaded more often on the
attitude “confident and accurate”. Intrapatient variability was
not correlated with the BAASIS classification of adherent
versus nonadherent patients (𝜒2(1) = 2.88, 𝑃 = 0.110).
3.4. Clinical Endpoints. Patients that reported nonadherence
in the BAASIS©-interview (𝑛 = 19) had a lower two-year
graft survival (failure 𝑛 = 3) compared to the adherent group
(failure 𝑛 = 2) (84% versus 98%, resp.) (𝜒2(1) = 6.409; 𝑃 =
0.038). See Figure 2. Graft failure was not related to attitudes
(𝑃 = 0.532) or intrapatient variability (𝑃 = 0.159). Patients
with rejection (𝑛 = 35) had no significantly lower graft
survival (𝑃 = 0.167) and graft rejection was not correlated
with self-reported adherence (𝜒2(1) = 0.004; 𝑃 = 0.574), the
three attitudes (𝜒2(2) = 2.391; 𝑃 = 0.347), or intrapatient
variability (𝜒2(1) = 2.947; 𝑃 = 0.074).
4. Discussion
ThisQ-methodological study revealed three distinct attitudes
toward medication nonadherence as early as six weeks after
transplantation: (1) confident and accurate, (2) concerned
and vigilant, and (3) appearance oriented and assertive. We
observed association between these attitudes, but not with
self-reported adherence and clinical outcomes 2 years after
transplantation. Patients with the attitude “confident and
accurate” appeared not to have no problems with medication
adherence. They were confident about managing their medi-
cation regime 6weeks after transplantation and these patients
had significantly lower variability of tacrolimus in their
blood. Earlier research has suggested that lower variability
indicates greater adherence [24]. In the attitude “concerned
and vigilant” we found evidence for a relationship between
anxiety about the medication regime and nonadherence, as
indicated by the significantly higher variability of tacrolimus
in the blood of these patients. DiMatteo et al. [25] also found
a difference in risk of nonadherence between anxious and

















Self-reported adherence versus nonadherence
Nonadherent
Adherent
Figure 2: Kaplan-Meier Graft survival. The nonadherent group
consisted of 19 patients (3 graft failures) and the adherent group
consisted of 94 patients (2 graft failures).
about their future and that this translated into frequent
monitoring, fear of forgetting, and noncompliance. In our
study, significantly more patients with a high intrapatient
variability loaded on this “concerned and vigilant” attitude.
These findings suggest that individuals characterised by
anxiety about their medication regime may be less adherent
or, alternatively, that patients who have more problems
with their medication are more worried. This association
between attitude and adherence was, however, only found
when adherence was measured using levels of medication
found in the blood, not when using self-report. Although the
patients defining attitude 2 seem to indicate they are reliable
in their medication taking, the high intra-patient variability
in the pharmacokinetics of tacrolimus suggests differently.
This discrepancy suggests a potential underreporting of
nonadherence in this group on the self-report measure.
Several studies before have found differences between self-
reported nonadherence, which is simpler to measure but
more susceptible to error, and direct measures for defining
nonadherence such as drug levels or a clinical indicator,
which are more objective and accurate but expensive [19,
26, 27]. Patients with the attitude “appearance oriented and
assertive” want to live a normal life, be in control, and
think they are capable of taking care of their kidney, and
they are also the patients that indicate experiencing side
effects. Although their intrapatient variability of tacrolimus
was not elevated, we speculate that these patients may have
a higher risk of nonadherence in the future because they are
8 Journal of Transplantation
concerned about (cosmetic) side effects of their medication
regimen.
The Q-methodology study thus uncovered different atti-
tudes towards medication adherence, which were associated
with intrapatient variability of tacrolimus but not with self-
reported nonadherence and with clinical endpoints such as
graft rejection or graft survival. In contrast, self-reported
nonadherence 6 weeks after transplantation was associated
with graft failure in the subsequent 2-year period, but
variability of tacrolimus was not.
The findings reported should be interpreted in the light
of a number of limitations. Firstly, as discussed, there is a
possibility of underreporting nonadherence given the clinical
setting of the study and the possibility of socially desirable
answers. The BAASIS scale was developed with this phe-
nomenon in mind and is therefore intentionally strict in its
scoring mechanism: even a small deviation in the regime
leads to being classified as nonadherent [20]. However, these
scores were not associated with intrapatient variability of
tacrolimus, a direct and potentially more objective measure
for adherence, so that underreporting cannot be dismissed.
Secondly, patients who did not have sufficient mastery of
the Dutch language were excluded and another group of
patients declined to participate. It is possible that these
harder-to-reach patients demonstrate yet another attitude,
not identified here. Findings therefore cannot be generalised
to these patients. Finally, this study was conducted among
a limited number of patients in a single centre. Replication
of this study in different centres, with particular attention to
inclusion of the harder-to-reach patients as well, is therefore
advised.
There are a few clinical implications of these findings.
We found that Q-methodology was a useful tool for nurses
in their interactions with patients, as it helped patients to
talk freely about a difficult clinical topic. This approach
offered patients the opportunity to (visually) structure their
thoughts and nurse researchers the opportunity to investigate
such pertinent issues in greater depth and to develop and
tailor education programmes for this patient population. In
any case, the finding that self-reported nonadherence was
related to likelihood of graft failure suggests that a dialog
between nurse and patient on medication adherence early
in the transplant recovery period could be a useful tool to
flag up individuals at risk of graft failure. Future research is
also needed to further explore the (reciprocal) relationship
between worry/anxiety and nonadherence and its clinical
consequences.
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